Fellow

Head of the Academic Unit of Ophthalmology at the University of Bristol, Andrew Dick has sustained his position as the leading ocular immunologist and translational physician in England & Wales and his position as a clinician/scientist in the introduction of novel biologic therapy for severe sight threatening ocular inflammatory disease remains unchallenged. Having developed this field in the first instance some ten-twelve years ago he continues to investigate and introduce other potential and better treatments for patients under his care, most recently by the development of pre-clinical studies using a novel agonist monoclonal antibody to the macrophage regulator for CD200. In this instance he exemplifies the practice of translational medicine. In recent years he has moved into the field of tissue regeneration and is part of a leading group in which he and his team have identified important neural progenitor cells in the retina. This has exciting potential for future treatment of many ocular and even non-ocular disorders. Professor Andrew Dick’s status as a clinician/scientist is of the highest order and he will continue to imprint a lasting stamp in the field of medicine in the UK.